Celularity Inc. (CELU)Healthcare | Biotechnology | Florham Park, United States | NasdaqCM
1.58 USD
-0.52
(-24.762%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.49 -0.09 (-0.090%) ⇩ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:55 a.m. EDT
Celularity presents a catastrophic investment case driven by a complete collapse in business fundamentals and severe corporate distress. The company has suffered a 96% loss in value over the last six years, with revenue shrinking by 77% and operating margins remaining deeply negative. The balance sheet is broken, with debt nearly 12 times the cash on hand and a negative book value, signaling that the equity has little intrinsic worth. Compounding these financial failures is an existential threat: the company faces delisting from Nasdaq due to non-compliance with listing rules, a status confirmed by recent news regarding deregistration notices. While the stock recently rallied on a narrow loss in earnings, this was likely a technical bounce rather than a sign of health, especially given the deteriorating revenue outlook. The options market reflects this despair, with traders aggressively buying protection via puts while avoiding any exposure to upside. With no dividend to provide income and a trajectory pointing toward erasure from the major exchanges, this security offers no rational entry point for investors. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.226088 |
| MSTL | 0.358893 |
| AutoETS | 0.367861 |
| AutoARIMA | 0.367867 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 0.35 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.387 |
| Excess Kurtosis | -0.74 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 1.037 |
| Market Cap | 45,734,620 |
| Forward P/E | -2.77 |
| Beta | 0.54 |
| Previous Name | GX Acquisition Corp. |
| Website | https://www.celularity.com |
As of Aug. 22, 2026, 2:55 a.m. EDT: Speculators are overwhelmingly bearish, positioning heavy put volume relative to negligible call activity. The implied volatility for puts is significantly elevated compared to calls, indicating a fear of further downside. Open interest is concentrated in out-of-the-money puts for the November expiration, while call activity is virtually non-existent, suggesting a lack of conviction in any near-term recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.17647058 |
| Address1 | 170 Park Avenue |
| All Time High | 134.0 |
| All Time Low | 0.56 |
| Ask | 1.62 |
| Ask Size | 2 |
| Audit Risk | 10 |
| Average Daily Volume10 Day | 22,267,560 |
| Average Daily Volume3 Month | 3,679,809 |
| Average Volume | 3,679,809 |
| Average Volume10Days | 22,267,560 |
| Beta | 0.541 |
| Bid | 1.2 |
| Bid Size | 1 |
| Board Risk | 10 |
| Book Value | -1.32 |
| City | Florham Park |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.58 |
| Current Ratio | 0.153 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.2 |
| Day Low | 1.48 |
| Display Name | Celularity |
| Earnings Timestamp End | 1,755,547,200 |
| Earnings Timestamp Start | 1,755,547,200 |
| Ebitda | -54,013,000 |
| Ebitda Margins | -2.03439 |
| Enterprise To Ebitda | -2.121 |
| Enterprise To Revenue | 4.315 |
| Enterprise Value | 114,572,616 |
| Eps Forward | -0.57 |
| Eps Trailing Twelve Months | -2.73 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.75276 |
| Fifty Day Average Change | 0.82724005 |
| Fifty Day Average Change Percent | 1.0989426 |
| Fifty Two Week Change Percent | -17.647058 |
| Fifty Two Week High | 3.154 |
| Fifty Two Week High Change | -1.574 |
| Fifty Two Week High Change Percent | -0.49904883 |
| Fifty Two Week Low | 0.56 |
| Fifty Two Week Low Change | 1.02 |
| Fifty Two Week Low Change Percent | 1.8214285 |
| Fifty Two Week Range | 0.56 - 3.154 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,565,271,000,000 |
| Float Shares | 18,869,004 |
| Forward Eps | -0.57 |
| Forward P E | -2.77193 |
| Free Cashflow | 5,384,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 115 |
| Fullday Change | -0.52 |
| Fullday Change Percent | -24.7619 |
| Fullday Price | 1.49 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.24392 |
| Gross Profits | 6,476,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.37182 |
| Held Percent Institutions | 0.12885 |
| Implied Shares Outstanding | 28,945,961 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,709,164,800 |
| Last Split Factor | 1:10 |
| Long Business Summary | Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey. |
| Long Name | Celularity Inc. |
| Market | us_market |
| Market Cap | 45,734,620 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_408304689 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-08-29 |
| Net Income To Common | -91,800,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 60,233,650 |
| Open | 2.16 |
| Operating Cashflow | -13,254,000 |
| Operating Margins | -4.92154 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 908 768 2170 |
| Post Market Change | -0.09000003 |
| Post Market Change Percent | -5.6962047 |
| Post Market Price | 1.49 |
| Post Market Time | 1,787,961,586 |
| Prev Name | GX Acquisition Corp. |
| Previous Close | 2.1 |
| Price Hint | 4 |
| Price To Book | -1.1969696 |
| Price To Sales Trailing12 Months | 1.7225846 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.135 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.52 |
| Regular Market Change Percent | -24.7619 |
| Regular Market Day High | 2.2 |
| Regular Market Day Low | 1.48 |
| Regular Market Day Range | 1.48 - 2.2 |
| Regular Market Open | 2.16 |
| Regular Market Previous Close | 2.1 |
| Regular Market Price | 1.58 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 14,934,865 |
| Return On Assets | -0.30934998 |
| Revenue Growth | -0.774 |
| Revenue Per Share | 1.037 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 28,945,961 |
| Shares Percent Shares Out | 0.0139 |
| Shares Short | 403,568 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 419,533 |
| Short Name | Celularity Inc. |
| Short Percent Of Float | 0.060599998 |
| Short Ratio | 10.24 |
| Source Interval | 15 |
| State | NJ |
| Symbol | CELU |
| Total Cash | 6,175,000 |
| Total Cash Per Share | 0.213 |
| Total Debt | 74,713,000 |
| Total Revenue | 26,550,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.73 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.134935 |
| Two Hundred Day Average Change | 0.44506502 |
| Two Hundred Day Average Change Percent | 0.39215022 |
| Type Disp | Equity |
| Volume | 14,934,865 |
| Website | https://www.celularity.com |
| Zip | 7,932 |